Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

NCT06882915 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer (CRC)

Interventions

DRUG: Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University